Natera, Inc. (NASDAQ:NTRA) Given Average Rating of “Buy” by Brokerages

Natera, Inc. (NASDAQ:NTRA) has been assigned a consensus rating of “Buy” from the seventeen brokerages that are currently covering the firm, MarketBeat Ratings reports. Seventeen research analysts have rated the stock with a buy rating. The average 12 month price objective among brokers that have covered the stock in the last year is $137.65.

A number of analysts have recently commented on the company. Piper Sandler restated an “overweight” rating and issued a $150.00 price target on shares of Natera in a report on Friday, September 13th. Leerink Partners lifted their target price on Natera from $140.00 to $150.00 and gave the company an “outperform” rating in a research report on Thursday, October 17th. UBS Group reduced their price target on Natera from $160.00 to $145.00 and set a “buy” rating for the company in a research report on Friday, August 9th. Stephens reiterated an “overweight” rating and issued a $125.00 price objective on shares of Natera in a report on Friday, August 9th. Finally, Canaccord Genuity Group upped their price objective on Natera from $150.00 to $165.00 and gave the stock a “buy” rating in a research note on Wednesday.

Insider Buying and Selling at Natera

In other Natera news, CEO Steven Leonard Chapman sold 4,728 shares of the stock in a transaction on Friday, November 15th. The stock was sold at an average price of $146.41, for a total transaction of $692,226.48. Following the transaction, the chief executive officer now owns 185,034 shares in the company, valued at $27,090,827.94. This trade represents a 2.49 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Michael Burkes Brophy sold 608 shares of Natera stock in a transaction on Monday, October 21st. The stock was sold at an average price of $120.76, for a total value of $73,422.08. Following the sale, the chief financial officer now directly owns 74,014 shares of the company’s stock, valued at $8,937,930.64. This represents a 0.81 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 36,821 shares of company stock valued at $4,776,878 in the last three months. 7.60% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the business. Itau Unibanco Holding S.A. acquired a new stake in Natera during the second quarter worth approximately $28,000. Quarry LP lifted its position in shares of Natera by 148.4% during the 2nd quarter. Quarry LP now owns 318 shares of the medical research company’s stock valued at $34,000 after acquiring an additional 190 shares during the period. GAMMA Investing LLC grew its holdings in shares of Natera by 50.0% during the 2nd quarter. GAMMA Investing LLC now owns 324 shares of the medical research company’s stock worth $35,000 after purchasing an additional 108 shares in the last quarter. Covestor Ltd increased its position in shares of Natera by 34.3% in the third quarter. Covestor Ltd now owns 372 shares of the medical research company’s stock worth $47,000 after purchasing an additional 95 shares during the period. Finally, True Wealth Design LLC bought a new position in shares of Natera in the third quarter worth $57,000. Institutional investors and hedge funds own 99.90% of the company’s stock.

Natera Price Performance

NASDAQ NTRA opened at $146.06 on Friday. The company has a debt-to-equity ratio of 0.33, a quick ratio of 4.01 and a current ratio of 4.39. The stock has a market cap of $19.28 billion, a price-to-earnings ratio of -82.99 and a beta of 1.53. The business has a 50 day simple moving average of $127.38 and a 200 day simple moving average of $115.46. Natera has a 52-week low of $52.01 and a 52-week high of $167.79.

Natera (NASDAQ:NTRA) last issued its quarterly earnings data on Tuesday, November 12th. The medical research company reported ($0.26) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.57) by $0.31. The company had revenue of $439.80 million during the quarter, compared to the consensus estimate of $361.43 million. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. The firm’s revenue was up 63.9% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.95) earnings per share. Analysts anticipate that Natera will post -1.96 earnings per share for the current fiscal year.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.